NYSEAMERICAN:OCX - OncoCyte Stock Price, Price Target & More

$2.45 -0.05 (-2.00 %)
(As of 04/22/2018 06:41 AM ET)
Previous Close$2.45
Today's Range$2.40 - $2.5450
52-Week Range$1.10 - $7.85
Volume19,869 shs
Average Volume69,289 shs
Market Capitalization$67.57 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About OncoCyte (NYSEAMERICAN:OCX)

OncoCyte logoOncoCyte Corporation focuses on the discovery, development, and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using proprietary sets of genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.

Receive OCX News and Ratings via Email

Sign-up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNYSEAMERICAN:OCX
CUSIPN/A
Phone+1-510-7750515

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-404.76%
Return on Assets-209.93%

Miscellaneous

EmployeesN/A
Outstanding Shares31,470,000

How to Become a New Pot Stock Millionaire

OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions

What is OncoCyte's stock symbol?

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

How were OncoCyte's earnings last quarter?

OncoCyte (NYSEAMERICAN:OCX) issued its earnings results on Monday, April, 2nd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.00. View OncoCyte's Earnings History.

When is OncoCyte's next earnings date?

OncoCyte is scheduled to release their next quarterly earnings announcement on Friday, April, 27th 2018. View Earnings Estimates for OncoCyte.

What price target have analysts set for OCX?

2 brokers have issued 12-month price objectives for OncoCyte's shares. Their predictions range from $7.75 to $7.75. On average, they expect OncoCyte's share price to reach $7.75 in the next twelve months. View Analyst Ratings for OncoCyte.

Are investors shorting OncoCyte?

OncoCyte saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 854,481 shares, an increase of 5.9% from the March 15th total of 807,018 shares. Based on an average trading volume of 251,899 shares, the short-interest ratio is currently 3.4 days. Approximately 10.2% of the shares of the stock are sold short.

Who are some of OncoCyte's key competitors?

Who are OncoCyte's key executives?

OncoCyte's management team includes the folowing people:
  • Mr. William Annett MBA, Pres, Chief Exec. Officer & Director (Age 64)
  • Dr. Kristine C. Mechem Ph.D., VP of Marketing & Planninng
  • Dr. Lyndal K. Hesterberg Ph.D., Sr. VP of R&D
  • Mr. Mitchell S. Levine, Chief Financial Officer
  • Mr. Michael G. Vicari, VP of Sales

Has OncoCyte been receiving favorable news coverage?

Press coverage about OCX stock has trended positive this week, according to Accern. The research firm identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. OncoCyte earned a coverage optimism score of 0.25 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 47.45 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of OncoCyte?

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $2.45.

How big of a company is OncoCyte?

OncoCyte has a market capitalization of $67.57 million.

How can I contact OncoCyte?

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-7750515.


MarketBeat Community Rating for OncoCyte (OCX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  79 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  149
MarketBeat's community ratings are surveys of what our community members think about OncoCyte and other stocks. Vote "Outperform" if you believe OCX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

OncoCyte (NYSEAMERICAN:OCX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for OncoCyte in the last 12 months. Their average twelve-month price target is $7.75, suggesting that the stock has a possible upside of 216.33%. The high price target for OCX is $7.75 and the low price target for OCX is $7.75. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.503.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.75$7.75$7.75$7.75
Price Target Upside: 216.33% upside252.27% upside5.44% upside5.44% upside

OncoCyte (NYSEAMERICAN:OCX) Consensus Price Target History

Price Target History for OncoCyte (NYSEAMERICAN:OCX)

OncoCyte (NYSEAMERICAN:OCX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
3/21/2018Janney Montgomery ScottDowngradeBuy -> NeutralView Rating Details
5/23/2017Chardan CapitalBoost Price TargetBuy$6.50 -> $7.75View Rating Details
1/30/2017Canaccord GenuityReiterated RatingBuyView Rating Details
6/7/2016BenchmarkBoost Price TargetSpeculative Buy$7.50 -> $8.00View Rating Details
(Data available from 4/22/2016 forward)

Earnings

OncoCyte (NYSEAMERICAN:OCX) Earnings History and Estimates Chart

Earnings by Quarter for OncoCyte (NYSEAMERICAN:OCX)

OncoCyte (NYSEAMERICAN OCX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/27/2018        
4/2/2018Q4 2017($0.1320)($0.13)ViewListenView Earnings Details
11/14/2017Q3 2017($0.13)($0.12)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.12)($0.13)ViewN/AView Earnings Details
4/28/2017Q1 2017($0.13)($0.16)ViewN/AView Earnings Details
2/27/2017Q4 2016($0.11)($0.11)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.10)($0.10)ViewN/AView Earnings Details
8/11/2016Q2 2016($0.11)($0.10)ViewN/AView Earnings Details
5/16/2016Q1 2016($0.11)($0.12)ViewN/AView Earnings Details
3/30/2016($0.09)($0.14)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

OncoCyte (NYSEAMERICAN:OCX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

OncoCyte (NYSEAMERICAN OCX) Insider Trading and Institutional Ownership History

Insider Trading History for OncoCyte (NYSEAMERICAN:OCX)

OncoCyte (NYSEAMERICAN OCX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/28/2018Broadwood Partners, L.P.Major ShareholderBuy3,968,254$1.26$5,000,000.04View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

OncoCyte (NYSEAMERICAN OCX) News Headlines

Source:
DateHeadline
Zacks Investment Research Upgrades OncoCyte (OCX) to HoldZacks Investment Research Upgrades OncoCyte (OCX) to Hold
www.americanbankingnews.com - April 17 at 12:40 AM
Short Interest in OncoCyte (OCX) Rises By 5.9%Short Interest in OncoCyte (OCX) Rises By 5.9%
www.americanbankingnews.com - April 11 at 2:50 AM
BRIEF-Oncocyte Reports Fourth Quarter Loss Of $0.13 Per ShareBRIEF-Oncocyte Reports Fourth Quarter Loss Of $0.13 Per Share
www.reuters.com - April 4 at 2:19 PM
BRIEF-Ronnie Andrews Appointed To Oncocyte Corps BoardBRIEF-Ronnie Andrews Appointed To Oncocyte Corp's Board
www.reuters.com - April 3 at 10:57 AM
OncoCyte Reports Fourth Quarter and Full Year 2017 Financial ResultsOncoCyte Reports Fourth Quarter and Full Year 2017 Financial Results
globenewswire.com - April 3 at 10:57 AM
Leading Molecular Diagnostics Executive Ronnie Andrews Appointed to OncoCyte’s Board of DirectorsLeading Molecular Diagnostics Executive Ronnie Andrews Appointed to OncoCyte’s Board of Directors
finance.yahoo.com - April 3 at 10:57 AM
Leading Molecular Diagnostics Executive Ronnie Andrews Appointed to OncoCytes Board of DirectorsLeading Molecular Diagnostics Executive Ronnie Andrews Appointed to OncoCyte's Board of Directors
feeds.benzinga.com - April 3 at 7:51 AM
OncoCyte (OCX) Posts Quarterly  Earnings Results, Hits EstimatesOncoCyte (OCX) Posts Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - April 3 at 7:46 AM
OncoCyte EPS in-lineOncoCyte EPS in-line
seekingalpha.com - April 2 at 4:46 PM
OncoCyte Names Cavan Redmond Chairman of the Board of DirectorsOncoCyte Names Cavan Redmond Chairman of the Board of Directors
globenewswire.com - April 2 at 11:04 AM
Does OncoCyte Corporation’s (NYSEMKT:OCX) CEO Pay Compare Well With Peers?Does OncoCyte Corporation’s (NYSEMKT:OCX) CEO Pay Compare Well With Peers?
finance.yahoo.com - March 31 at 10:28 AM
OncoCyte Corp (OCX) Major Shareholder Purchases $5,000,000.04 in StockOncoCyte Corp (OCX) Major Shareholder Purchases $5,000,000.04 in Stock
www.americanbankingnews.com - March 30 at 10:16 PM
OncoCyte (OCX) Cut to Hold at Zacks Investment ResearchOncoCyte (OCX) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - March 30 at 11:06 AM
OncoCyte (OCX) Upgraded to Buy at Zacks Investment ResearchOncoCyte (OCX) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - March 28 at 10:26 AM
OncoCyte Corp (OCX) Sees Large Increase in Short InterestOncoCyte Corp (OCX) Sees Large Increase in Short Interest
www.americanbankingnews.com - March 26 at 6:32 PM
What You Must Know About OncoCyte Corporation’s (NYSEMKT:OCX) Market RisksWhat You Must Know About OncoCyte Corporation’s (NYSEMKT:OCX) Market Risks
finance.yahoo.com - March 23 at 10:09 AM
OncoCyte (OCX) Downgraded by Janney Montgomery Scott to "Neutral"OncoCyte (OCX) Downgraded by Janney Montgomery Scott to "Neutral"
www.americanbankingnews.com - March 21 at 4:58 PM
OncoCyte Corporation (NYSEMKT:OCX) Is Expected To BreakevenOncoCyte Corporation (NYSEMKT:OCX) Is Expected To Breakeven
finance.yahoo.com - March 15 at 10:01 AM
OncoCyte Announces Initial Results of DetermaVu™ Feasibility on New Platforms; Enhancements May Increase Lung Cancer Diagnostic Test’s Clinical PerformanceOncoCyte Announces Initial Results of DetermaVu™ Feasibility on New Platforms; Enhancements May Increase Lung Cancer Diagnostic Test’s Clinical Performance
finance.yahoo.com - March 9 at 3:42 PM
OncoCyte Corp (OCX) Sees Significant Growth in Short InterestOncoCyte Corp (OCX) Sees Significant Growth in Short Interest
www.americanbankingnews.com - February 28 at 1:56 AM
OncoCyte (OCX) Set to Announce Earnings on MondayOncoCyte (OCX) Set to Announce Earnings on Monday
www.americanbankingnews.com - February 19 at 5:04 AM
OncoCyte Corp (OCX) Sees Large Growth in Short InterestOncoCyte Corp (OCX) Sees Large Growth in Short Interest
www.americanbankingnews.com - February 10 at 1:18 AM
OncoCyte Co. (OCX) Short Interest UpdateOncoCyte Co. (OCX) Short Interest Update
www.americanbankingnews.com - January 24 at 5:40 PM
OncoCyte (OCX) Lifted to "Buy" at Zacks Investment ResearchOncoCyte (OCX) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 13 at 9:26 AM
Short Interest in OncoCyte Co. (OCX) Expands By 47.1%Short Interest in OncoCyte Co. (OCX) Expands By 47.1%
www.americanbankingnews.com - January 10 at 6:04 PM
OncoCyte (OCX) Lowered to "Hold" at Zacks Investment ResearchOncoCyte (OCX) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 9 at 9:02 AM
OncoCyte (OCX) Upgraded by Zacks Investment Research to BuyOncoCyte (OCX) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - January 6 at 9:56 AM
What Is The Future Prospect For Healthcare And OncoCyte Corporation (NYSEMKT:OCX)?What Is The Future Prospect For Healthcare And OncoCyte Corporation (NYSEMKT:OCX)?
finance.yahoo.com - January 5 at 10:20 AM
OncoCyte Co. (OCX) Short Interest Up 58.5% in NovemberOncoCyte Co. (OCX) Short Interest Up 58.5% in November
www.americanbankingnews.com - December 11 at 7:58 PM
OncoCyte Presents Positive Data from its Liquid Biopsy Breast Cancer Diagnostic Test at the San Antonio Breast Cancer SymposiumOncoCyte Presents Positive Data from its Liquid Biopsy Breast Cancer Diagnostic Test at the San Antonio Breast Cancer Symposium
finance.yahoo.com - December 7 at 8:55 AM
Additional Renevia Data From the Successful Pivotal Trial Was Presented at the IFATS ConferenceAdditional Renevia Data From the Successful Pivotal Trial Was Presented at the IFATS Conference
www.businesswire.com - December 4 at 8:50 AM
OncoCyte Initiates Search for New Independent DirectorOncoCyte Initiates Search for New Independent Director
finance.yahoo.com - November 29 at 5:01 PM
OncoCyte Corporation to Participate in the Benchmark Company, LLC Micro Cap Discovery One-on-One ConferenceOncoCyte Corporation to Participate in the Benchmark Company, LLC Micro Cap Discovery One-on-One Conference
finance.yahoo.com - November 27 at 4:42 PM
Seasoned Financial Executive Joins OncoCyte as Chief Financial OfficerSeasoned Financial Executive Joins OncoCyte as Chief Financial Officer
finance.yahoo.com - November 18 at 10:08 AM
OncoCyte Corp (OCX) Lowered to Sell at Zacks Investment ResearchOncoCyte Corp (OCX) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - November 18 at 6:06 AM
BRIEF-Oncocyte Q3 loss per share $0.22BRIEF-Oncocyte Q3 loss per share $0.22
www.reuters.com - November 15 at 7:02 AM
OncoCytes (OCX) CEO Bill Annett on Q3 2017 Results - Earnings Call TranscriptOncoCyte's (OCX) CEO Bill Annett on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 15 at 7:02 AM
OncoCyte Reports Third Quarter 2017 Financial ResultsOncoCyte Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 15 at 7:02 AM

SEC Filings

OncoCyte (NYSEAMERICAN:OCX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

OncoCyte (NYSEAMERICAN:OCX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

OncoCyte (NYSEAMERICAN OCX) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.